Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Hiroaki Yanagimoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6493-4732; OpenAlex author ID A5028936803, A5124305778. Sources: OpenAlex.

Their work

Papers
54 (first author 9, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
137
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 2 papers · 2014: 4 papers · 2015: 5 papers · 2016: 8 papers · 2017: 6 papers · 2018: 2 papers · 2019: 4 papers · 2020: 1 paper · 2021: 4 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 5 papers

Papers 50 of 54

  1. Learning Curve Effect in Reducing Local Recurrence Rate After Resection of Pancreatic Cancer With Arterial Abutment: A Single-Center Retrospective Study. Co-author DOI 10.1002/ags3.70100↗
  2. Intraoperative frozen section analysis of the portal or superior mesenteric vein transection margin in pancreatectomy with venous resection for pancreatic canc… Co-author DOI 10.1016/j.gassur.2026.102410↗
  3. Short- and Long-Term Outcomes after Pancreatectomy for Pancreatic Cancer in Patients with Prior Esophagectomy for Esophageal Cancer. Co-author DOI 10.1245/s10434-025-18491-3↗
  4. ASO Visual Abstract: Short- and Long-Term Outcomes after Pancreatectomy for Pancreatic Cancer in Patients with Prior Esophagectomy for Esophageal Cancer. Co-author DOI 10.1245/s10434-025-18718-3↗
  5. Delayed Initiation of S-1 Adjuvant Chemotherapy Impairs Survival in Patients With Curatively Resected Pancreatic Cancer. Co-author DOI 10.21873/anticanres.18004↗
  6. Prognostic Significance of GLIM-Defined Malnutrition in Patients With Resectable Pancreatic Adenocarcinoma Following Upfront Surgery. Co-author DOI 10.1002/ags3.70059↗
  7. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  8. Preoperative level of serum transthyretin as a novel biomarker predicting survival in resected pancreatic ductal adenocarcinoma with neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2024.07.012↗
  9. Clinicopathological variables and risk factors for lung recurrence after resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.asjsur.2022.03.043↗
  10. Efficacy of Lentinula edodes Mycelia Extract on Chemotherapy-Related Tasted Disorders in Pancreatic Cancer Patients. Co-author DOI 10.1080/01635581.2022.2107226↗
  11. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  12. Increased expression of SPRR1A is associated with a poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0266620↗
  13. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  14. Clinicopathological characteristics of pancreatic ductal adenocarcinoma with invasive micropapillary carcinoma component with emphasis on the usefulness of PKC… Co-author DOI 10.3892/ol.2021.12786↗
  15. [A Patient with Ascending Jejunal Mesentery Metastasis of Pancreatic Cancer after a Subtotal Stomach-Preserving Pancreaticoduodenectomy]. Co-author PMID 35045476↗
  16. [A Case of Pancreatic Cancer with Gastric Wall Recurrence after Laparoscopic Distal Pancreatectomy Due to Needle Tract Seeding following EUS-FNA]. Co-author PMID 35045477↗
  17. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12061428↗
  18. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively … Co-author DOI 10.1007/s00268-018-4814-4↗
  19. Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis. Co-author DOI 10.1016/j.pan.2019.03.001↗
  20. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicente… Co-author DOI 10.1186/s12885-019-5460-4↗
  21. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2018-0900↗
  22. Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgica… Co-author DOI 10.1016/j.pan.2017.11.005↗
  23. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Stud… Co-author DOI 10.1158/2326-6066.cir-17-0386↗
  24. Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospectiv… First author DOI 10.1002/jhbp.447↗
  25. Retrospective Study of the Correlation Between Pathological Tumor Size and Survival After Curative Resection of T3 Pancreatic Adenocarcinoma: Proposal for Recl… Co-author DOI 10.1007/s00268-017-4077-5↗
  26. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patien… Co-author DOI 10.1007/s00280-017-3250-8↗
  27. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy. First author DOI 10.1007/s00595-016-1358-9↗
  28. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive de… First author DOI 10.1007/s10147-017-1112-3↗
  29. Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. Co-author DOI 10.1097/sla.0000000000001705↗
  30. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreati… Co-author DOI 10.1002/jhbp.318↗
  31. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. Co-author DOI 10.1002/jhbp.320↗
  32. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal ade… Co-author DOI 10.1002/jhbp.408↗
  33. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic … Co-author DOI 10.1007/s00280-015-2928-z↗
  34. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Co-author DOI 10.1007/s00280-016-3121-8↗
  35. Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarc… Co-author DOI 10.1080/01635581.2016.1134597↗
  36. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Grou… Co-author DOI 10.1097/mpa.0000000000000579↗
  37. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. First author DOI 10.1186/s12957-016-0767-y↗
  38. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. Co-author DOI 10.1007/s00535-014-1005-4↗
  39. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. Co-author DOI 10.1007/s11605-014-2637-7↗
  40. Potential role of surgical resection for pancreatic cancer in the very elderly. Co-author DOI 10.1016/j.pan.2015.03.015↗
  41. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2015.103↗
  42. Impact of Preoperative Biliary Drainage on Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma: A Multicenter Observational Study. Co-author DOI 10.1245/s10434-015-4618-9↗
  43. Role of adjuvant surgery in initially unresectable pancreatic cancer after long-term chemotherapy or chemoradiation therapy: survival benefit? Co-author DOI 10.1002/jhbp.119↗
  44. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. Co-author DOI 10.1002/jhbp.130↗
  45. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-013-2323-6↗
  46. Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000125↗
  47. Activation of alpha-smooth muscle actin-positive myofibroblast-like cells after chemotherapy with gemcitabine in a rat orthotopic pancreatic cancer model. Co-author DOI 10.1007/s00534-012-0576-9↗
  48. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗
  49. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer. Co-author DOI 10.1007/s11605-011-1795-0↗
  50. Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection. First author DOI 10.1016/j.jss.2010.09.027↗

Closest collaborators

The 25 strongest of 137 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takumi Fukumoto · 19 shared papers, 2015–2026 · strength 2.69
  2. Jun Ishida · 10 shared papers, 2021–2026 · strength 2.11
  3. Hirochika Toyama · 11 shared papers, 2018–2026 · strength 2.09
  4. Sadaki Asari · 9 shared papers, 2021–2026 · strength 1.82
  5. Sohei Satoi · 34 shared papers, 2011–2021 · strength 1.79
  6. Takuya Mizumoto · 7 shared papers, 2024–2026 · strength 1.75
  7. Yoshihide Nanno · 7 shared papers, 2024–2026 · strength 1.75
  8. Tomohisa Yamamoto · 26 shared papers, 2011–2023 · strength 1.56
  9. So Yamaki · 21 shared papers, 2011–2023 · strength 1.38
  10. Satoshi Hirooka · 20 shared papers, 2011–2023 · strength 1.29
  11. Dongha Lee · 5 shared papers, 2025–2026 · strength 1.27
  12. Masayuki Sho · 17 shared papers, 2013–2019 · strength 0.87
  13. Hironori Ryota · 9 shared papers, 2016–2021 · strength 0.67
  14. Masanori Kon · 11 shared papers, 2016–2018 · strength 0.66
  15. Michiaki Unno · 12 shared papers, 2015–2019 · strength 0.64
  16. Ippei Matsumoto · 10 shared papers, 2015–2023 · strength 0.63
  17. Hiroki Yamaue · 12 shared papers, 2014–2019 · strength 0.63
  18. Masanao Kurata · 10 shared papers, 2015–2019 · strength 0.55
  19. Fuyuhiko Motoi · 10 shared papers, 2015–2019 · strength 0.55
  20. Goro Honda · 10 shared papers, 2015–2019 · strength 0.55
  21. Yoshiaki Murakami · 9 shared papers, 2015–2019 · strength 0.49
  22. Kenichiro Uemura · 9 shared papers, 2015–2019 · strength 0.49
  23. Minako Nagai · 9 shared papers, 2015–2019 · strength 0.49
  24. Masafumi Ikeda · 5 shared papers, 2013–2025 · strength 0.45
  25. A‐Hon Kwon · 13 shared papers, 2011–2015 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.